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Abstract
Background: In many patients suffering from primary headaches, the available pharmacological and behavioural treat-
ments are not satisfactory. This is a review of (minimally) invasive interventions targeting pericranial nerves that could be
effective in refractory patients.
Methods: The interventions we will cover have in common pericranial nerves as targets, but are distinct according to
their rationale, modality and invasiveness. They range from nerve blocks/infiltrations to the percutaneous implantation of
neurostimulators and surgical decompression procedures. We have critically analysed the published data (PubMed) on
their effectiveness and tolerability.
Results and conclusions: There is clear evidence for a preventative effect of suboccipital injections of local anaes-
thetics and/or steroids in cluster headache, while evidence for such an effect is weak in migraine. Percutaneous occipital
nerve stimulation (ONS) provides significant long-term relief in more than half of drug-resistant chronic cluster headache
patients, but no sham-controlled trial has tested this. The evidence that ONS has lasting beneficial effects in chronic
migraine is at best equivocal. Suboccipital infiltrations are quasi-devoid of side effects, while ONS is endowed with
numerous, though reversible, adverse events. Claims that surgical decompression of multiple pericranial nerves is
effective in migraine are not substantiated by large, rigorous, randomized and sham-controlled trials.
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Introduction
Primary headaches altogether represent the most
common neurological disorders and are usually asso-
ciated with disability, decreased quality of life and
ﬁnancial costs both for the aﬀected individual and for
society. Among primary headaches, migraine and clus-
ter headaches are the ones that more often aﬀect quality
of life, especially their chronic forms, which are fre-
quently associated with acute medication overuse and
low responsiveness to preventative pharmacological
treatments. Approximately 11% of all migraine
patients and approximately 1% of chronic cluster head-
ache (CCH) patients become refractory to all available
pharmacological treatments (1).
The management of migraine and cluster headache is
multifaceted. Besides advice on lifestyle, the manage-
ment of cluster headache is based on acute interven-
tions in order to alleviate the attack and preventative
treatments in order to reduce attack frequency and dis-
ability. However, the eﬃcacy of preventive drugs is
limited in many patients, and most of these pharmaco-
logical treatments can have cumbersome adverse eﬀects
(2). Alternative treatments have thus been used for
some time, but they have received increasing attention
only recently because of the lack of new advances in
pharmacotherapy.
Migraine and cluster headache are considered to be
central neurovascular disorders. The headache is likely
generated in the trigeminovascular system that cortical
(migraine) or subcortical (cluster headache) dysfunc-
tions are thought to activate (3). It was recently
shown that trigeminovascular meningeal aﬀerents pro-
ject through the skull (4) and that activation of these
extracranial aﬀerents in rats causes the release of calci-
tonin gene related peptide (CGRP) from the dura,
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suggesting that extracranial noxious signals may inﬂu-
ence meningeal nociception (5). Despite the scarcity of
data favouring a role for pericranial nerves in primary
headaches, these ﬁndings may oﬀer a rationale for the
various therapeutic interventions based on pericranial
nerves that have been used in refractory patients for
some time. Many patients indeed state that their pain
is localised to the surface of the head or neck, which is
in close anatomical relationship with branches of the
pericranial nerves. Although these superﬁcial pain loca-
tions were likely to represent referred pain from the
visceral part of the ophthalmic division of the trigem-
inal nerve, they led to surgical interventions on super-
ﬁcial cranial nerves for the treatment of migraine and
other headache types by as early as the ﬁrst half of the
20th century. Renowned physicians such as Cushing,
Penﬁeld or Rowbotham pioneered subtotal ophthalmic
nerve or cervical root rhizotomies, sections of supra-
orbital, supratrochlear or occipital nerves, excisions of
the stellate ganglion or pericarotid sympathectomies,
and even craniotomies (6). Various invasive lesional
procedures have also been performed over time in clus-
ter headache, targeting the trigeminal or cranial para-
sympathetic pathways and using radiofrequency
lesions, glycerol injections or balloon compressions of
the Gasserian ganglion, Gamma Knife surgery or sec-
tion of the trigeminal root, trigeminal tractotomy,
lesions of the nervus intermedius or greater superﬁcial
petrosal nerve, blockade or radiofrequency lesions of
the sphenopalatine ganglion and microvascular decom-
pression of the trigeminal nerve combined with nervus
intermedius section (7). Although spectacular results
were reported in some patients, most of them had a
mixture of diﬀerent headache types and few showed
satisfactory long-term results, despite the mutilating
character of the procedures (6).
We will focus here on some of the invasive interven-
tions that are used to treat migraine and cluster head-
ache and are supposed to act on pericranial nerve
branches. We have schematically ordered them accord-
ing to their increasing invasiveness from inﬁltrations/
blocks to percutaneous neurostimulations and surgical
decompressions.
Blocks and infiltrations
Peripheral nerve blocks have been used for some time in
order to treat headaches (8). In most studies they tar-
geted the greater occipital nerve (GON) because of the
known anatomo-physiological convergence of C2 der-
matoma and trigeminovascular aﬀerents in the spinal
trigeminal nucleus that underlies referred pain from the
neck to the orbitofrontal regions innervated by the oph-
thalmic nerve (9). Local anaesthetics are commonly
injected alone or in combination with corticosteroids.
The procedure is minimally invasive, inexpensive, safe
and it can be performed on an outpatient basis.
Migraine
The most relevant studies are summarized in Table 1
(10–14). Five controlled trials are available, but unfor-
tunately no standardised methods were used. The selec-
tion criteria of patients varied between studies (some
had ﬁxed unilateral headache, others not) and so did
the timing of the procedure (ictal or inter-ictal), the
technique of inﬁltrations or blocks (unilateral or bilat-
eral, associated blocks of other pericranial nerves or
trigger point injections, one or more interventions),
the compounds used for the blocks (local anaesthetics
alone or combined with diﬀerent types and dosages of
steroids) and the outcome measures (number of head-
ache-free days, percentage reduction of headache days
or attacks, non-standardised pain indices). A compari-
son of results between studies is therefore challenging.
Overall, a complete or partial beneﬁt for migraine
prevention was reported in 48–100% of adult migrain-
eurs, lasting from a few days to several months. A
retrospective study also found a partial beneﬁt
(<35%) from GON injections in paediatric chronic
migraineurs (15). In none of the controlled studies on
GON blocks was the addition of steroids found to be
superior to the injection of a local anaesthetic alone,
commonly used as placebo. In one controlled single-
blinded study, the beneﬁt was quite modest (10).
Similarly, in a placebo-controlled randomized double-
blinded trial performed in episodic (n¼ 54) and chronic
(n¼ 9) migraineurs, the block with steroids showed a
non-signiﬁcant percentage of >50% responders
(30%) (11). In a third randomised trial in episodic
migraine patients, 1.0mL of lidocaine 2% injected sub-
occipitally induced a similar decrease of pain severity
and frequency for up to 8 weeks, whether it was com-
bined with 0.5mL saline (control group: n¼ 24) or with
0.5mL triamcinolone (n¼ 24) (12).
Two recent double-blind placebo-controlled studies
comparing GON injections of saline (placebo) with
0.5% bupivacaine (verum) found that the latter pro-
vided partial beneﬁt in migraine patients. In the ﬁrst
study, chronic migraine patients received four weekly
injections (13). The number of headache days decreased
from 16.9 5.7 to 13.2 6.7 in the placebo group
(p¼ 0.035), but from 18.1 5.3 to 8.8 4.8 (p< 0.001)
in verum-treated patients, and the superior eﬀect of
bupivacaine was conﬁrmed in an open 2-month exten-
sion study. In the second study, patients suﬀering from
chronic refractory migraine had a single ultrasound-
guided GON block of saline or bupivacaine 0.5%.
Four weeks later, the average pain intensity score on
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































verum (n¼ 11; p¼ 0.003) but not in the placebo group
(n¼ 12; p¼ 0.110) (14).
Medication overuse was not associated with an
increased risk of failure of GON blocks in two studies
(16,17), but it tripled this risk in another study (18). The
presence of GON palpation tenderness was associated
with better outcome in one study (16), but not in two
others (12,17). The eﬀect of GON blocks on headache
frequency and intensity does not predict the success of
GON neurostimulation in chronic migraineurs (19).
GON blocks were also tested as a symptomatic treat-
ment for migraine attacks. In 14 patients who received
combined lidocaine blocks of the greater occipital nerve
and supraorbital nerve (SON), pain reduction after 30
minutes was almost signiﬁcant, but 50% of patients did
not respond at all (20). By contrast, in an open study in
which a GON block with 1 cc of a 50/50 mixture of 2%
lidocaine and 0.5% bupivacaine was administered to
patients with unilateral episodic or chronic migraine
and brush allodynia, headache intensity decreased on
average by 46.8% in 89.5% of patients after 20 minutes
and ipsilateral allodynia decreased by 65.7% in all
patients (21). The same group reported that the proced-
ure produced 64% and 75% reductions of pain and
allodynia scores, respectively, after 5 minutes and that
the beneﬁt lasted on average for 4 days, both in episodic
and chronic migraineurs (22). In a single case report,
GON inﬁltration with 3mL of 0.25% bupivacaine and
1mL of 40mg/mL triamcinolone induced partial reso-
lution of aura symptoms and complete disappearance of
the headache after a few minutes in a patient with basi-
lar-type migraine who was treated during an attack (23).
SON blocks have rarely been studied without con-
comitant GON blocks, so that their proper eﬃcacy is
diﬃcult to assess. The combination of GON and SON
blocks with 0.5–1.5mL of lidocaine (20mg/mL and
12.5 mg/mL adrenaline) had no beneﬁcial eﬀect in one
study (20). By contrast, in an open trial comparing
SON and GON blocks alone and their combination,
SON blocks alone reduced headache frequency by
50% in 68.75% of patients after 1 month and in 75%
of patients after 6 months (24). A further study
reported that three consecutive bilateral SON and
infraorbital nerve blocks with 1.5mL of 1% lidocaine
in episodic migraine patients were able to decrease sig-
niﬁcantly the mean headache frequency and migraine
disability assessment (MIDAS) score (25).
In a recent randomized, double-blind, placebo-
controlled trial, repetitive 0.5% bupivacaine block-
ades of the sphenopalatine ganglion with the Tx360
device twice a week for 6 weeks were compared to
saline injections in chronic migraine patients (26).
Slight but non-signiﬁcant reductions in headache days
and average pain scores were found in the bupivacaine
group.
Cluster headache
A large number of open studies – reviewed in Leroux
and Ducros (27) – found that GON blocks with steroids
were beneﬁcial as a transitional treatment during active
bouts in episodic cluster headache (ECH) and in CCH
patients who had an insuﬃcient response to classical
oral preventative drugs, while GON blocks solely
with local anaesthetics were ineﬀective (28–30). At pre-
sent, only two randomized, placebo-controlled studies
are available on GON blockade in cluster headache. In
the ﬁrst study, CCH (n¼ 7) and active ECH (n¼ 16)
patients were included (29). The verum group (n¼ 13)
received a single GON inﬁltration on the side of attacks
with a mixture containing a long-acting salt and a
rapid-acting salt of betamethasone (dipropionate
12.46mg and disodium phosphate 5.26mg, respect-
ively) mixed with 0.5mL of lidocaine 2%, while the
placebo-treated group received physiological saline
and 0.5mL of lidocaine 2%. The stringent outcome
measure of sustained attack-free state within 72 hours
for 4 weeks was fulﬁlled by 61.5% of steroid-injected
patients, contrasting with none of the placebo-treated
patients. A total of 85% of steroid-injected patients had
a remission after 72 hours for at least 1 week. Only
three patients out of the 11 who initially responded
had recurrence of attacks within the 4-week duration
of the trial. One additional patient was considered to be
a non-responder because his attacks did not disappear
within 72 hours of the injection, but he became asymp-
tomatic 1 day later. Five out of eight responders
remained in total remission for at least 6 months.
Among the ten patients who were injected with physio-
logical saline–lidocaine, none was attack-free after 1
week, and all of them needed additional prophylactic
treatment.
The second randomised controlled trial (RCT)
included 43 patients (28 ECH, 15 CCH) who received
three unilateral suboccipital injections 48–72 hours
apart of either cortivazol 3.75mg (verum group,
n¼ 21) or physiological saline (placebo group, n¼ 22)
(31). In the ﬁrst 2 weeks, patients in the cortivazol-trea-
ted group had on average a signiﬁcant reduction of
attack frequency (p¼ 0.004), and there was a trend
for a higher percentage of patients with a> 50% reduc-
tion of attacks compared to the placebo group (86% vs.
59%; p¼ 0.064). At day 30 after the injections, 76% of
cortivazol-treated and 59% of saline-treated patients
were in remission.
Comments
Most observational studies suggest that GON inﬁltra-
tions with local anaesthetics or steroids and, to a
lesser degree, SON blocks may be beneﬁcial in some
Ambrosini and Schoenen 5
migraine patients, but further studies are needed
in order to determine in which subgroups this beneﬁ-
cial eﬀect occurs. By contrast, in three out of ﬁve
controlled trials, the eﬀect of GON blockade was mar-
ginal. Given the available evidence, GON blocks
cannot be considered a ﬁrst-line treatment in migraine.
They are at best useful as an add-on therapy for the
treatment of status migrainosus or for short-term
prophylaxis in chronic migraine with medication over-
use, with the aim of reducing the consumption of symp-
tomatic drugs until preventative treatments become
eﬀective (32).
In two RCTs, GON inﬁltrations with steroids were
clearly superior to physiological saline (31) or a local
anaesthetic alone (29) in terms of interrupting a bout of
cluster headache. This contrasts with migraine, for
which some studies also reported a positive eﬀect of
the injection of a sole local anaesthetic.
Overall, GON blocks are well tolerated. Adverse
eﬀects are rare and minor, and include dizziness, local
pain and vaso-vagal pre-syncope. Alopecia was
reported in some patients who were injected superﬁ-
cially with triamcinolone; this can be avoided com-
pletely by injecting steroids in a deeper location close
to the anatomical area where the GON has a latero-




Electrical stimulation of peripheral nerves (PNS) is a
well-known and eﬃcacious way to relieve pain within
the territory of the stimulated nerve. Its eﬀect is
thought to be due to activation of aﬀerent Ab ﬁbres
and subsequent gate control mechanisms in the spinal
cord dorsal horn and/or activation of descending
supraspinal pain controls from the periaqueductal
grey and rostral ventromedial medulla (34,35).*
Visceral trigeminovascular aﬀerents converge with cer-
vical (C2) and somatic ophthalmic nerve aﬀerents on
second-order nociceptors in the spinal trigeminal
nucleus (36). There is thus, in theory, a rationale for
stimulation of the GON and/or the SON in migraine
and cluster headache.
Migraine
Invasive PNS was studied as a preventative ther-
apy quasi-exclusively in patients suﬀering from drug-
resistant chronic migraine.
In addition to a small, randomized open trial, only
three randomized sham-controlled trials have been
published, two in extenso and one in abstract form
(37–40).
In the open-label trial, 29 patients who did not
respond to at least two prophylactic treatments and
had beneﬁted from a preliminary temporary occipital
nerve stimulation (ONS) system were ameliorated when
the ONS device was switched on as compared to when
it was switched oﬀ, and these beneﬁts were conﬁrmed in
a 1-year follow-up (37). In the ONSTIM trial that
included 66 patients with a 12-week follow-up, 39%
of patients who received the active ONS had at least
a 50% decrease in headache frequency and headache
intensity, while there were no improvements in the
sham-stimulated and medically treated groups
(Table 2) (38). Unfortunately, ONSTIM was not pow-
ered to demonstrate eﬃcacy, but rather feasibility and
safety. By contrast, in the sham-controlled PRISM
study, in which 125 patients with drug-resistant chronic
migraine with or without medication overuse were
enrolled, there was no superiority of active ONS over
sham stimulation (39). The hitherto largest RCT of
ONS in 157 chronic migraine patients failed to reach
the primary endpoint (at least 50% reduction in mean
daily headache intensity), but a higher percentage of
patients in the active than in the sham arm achieved a
30% reduction in mean headache days (p< 0.05) and a
decrease in migraine-related disability score (MIDAS)
(p< 0.01) (40). After the 3-month randomised phase,
an open-label phase of 40 weeks showed a signiﬁcant
6.7-day reduction in monthly headache days in the
intention-to-treat group and a 7.7-day reduction in a
subgroup of patients with ‘intractable’ chronic migraine
(p< 0.01); 59.5% of patients had a 30% reduction in
headache days and/or pain intensity and 47.8% had a
50% reduction (41).
In order to test whether unblinding due to local par-
esthesias may inﬂuence outcome in ONS trials, supra-
threshold, subthreshold and no stimulation were
compared in a small randomised cross-over study of
eight patients suﬀering from chronic migraine. The
suprathreshold stimulation was found to be more
eﬀective than the subthreshold one, but the latter was
also superior to no stimulation (42).
A meta-analysis of the available RCTs and seven
case series (total of 517 patients) suggests a superiority
of real ONS over sham stimulation in chronic migraine
patients, but the average eﬀect size is modest and seems
to be smaller than that found in cluster headache (43).
The eﬀect of combined ONS and SON stimulation
(SNS) was assessed retrospectively in an open study of
44 patients with chronic migraine. The combination
was reported to reduce the frequency of severe head-
aches by 81% (44,45), with a nearly complete headache
disappearance in half of the patients (45). This impres-
sive result needs to be conﬁrmed in a RCT. Combined
ONS–SNS was found to be superior to ONS alone in a









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ambrosini and Schoenen 7
but patient selection and follow-up biases may have
inﬂuenced the results (46). The combined stimulation
was found to be useful in a case series of four drug-
resistant sporadic hemiplegic migraine patients (47).
This result also needs conﬁrmation, but it was hypoth-
esised that PNS might inhibit cortical spreading depres-
sion (48).
Cluster headache
The evidence for the eﬀectiveness of ONS in intractable
CCH (iCCH) comes from several open-label prospect-
ive studies (49–53) and three long-term follow-up
studies of the same patients (54–56). The ﬁrst sham-
controlled trial (ICON) is still ongoing (57). In one
trial, eight iCCH patients were implanted bilaterally:
six patients reported 20–95% ameliorations of attack
frequency and intensity after a follow-up of 6–27
months (49). In another pilot study, eight iCCH
patients were implanted unilaterally on the attack
side and prospectively followed for 3–22 months
using headache diaries (50). Two patients became
pain-free, three had a decrease in attack frequency of
approximately 90% and two had a decrease in
attack frequency of approximately 40%. Overall
attack intensity decreased by 50%. With ONS, all
of the patients could reduce preventative medications,
but not interrupt them completely. Transient side
shift of attacks occurred only in two patients. In
both studies, a clinical beneﬁt occurred after a delay
ranging from several weeks to several months post-
surgery.
In a multicentre prospective study involving 13
iCCH patients who were implanted bilaterally and fol-
lowed for 3–34 months, ten patients reported an ameli-
oration of attack intensity within a few days of the
surgery (51). Among the seven patients with a follow-
up of 12 months, two were headache-free, four had
a 50% reduction of attack frequency and one had a
30% reduction of attack frequency. At the long-term
follow-up, the treatment response was lost in two out of
these seven patients. In a small study of three patients,
two had a> 50% reduction in headache frequency
already at 1 month post-surgery, whereas the last one
responded after 3 months (52).
A trial with bilateral ONS including ten iCCH
patients showed beneﬁcial eﬀects in nine subjects,
with a mean overall improvement over time of 44%
(range: 20–90%) in terms of attack frequency; eight
patients also reported a decreased intensity of any
remaining attacks. ONS became eﬀective on average
at 20 days after surgery (53).
Three of these trials were subsequently extended to
other patients and longer follow-up (49,50,53). In the
study by Burns et al., nine out of 14 patients were
followed up for more than 12 months (54). Four of
them reported sustained a 50% improvement of
their headache. Magis et al., after long-term follow-up
(range: 11–64 months), reported complete remission of
attacks in eight patients out of 13 who had a follow-up
exceeding 12 months, and about 90% amelioration in
two patients, but most patients continued preventative
drugs and the intensity of residual attacks was not sig-
niﬁcantly reduced (55). Among the 17 patients who
were followed for at least 12 months during ONS,
Mueller et al. demonstrated that 15 showed a 50%
amelioration (56).
Some case reports of unilateral ONS-treated iCCH
patients with moderate to high beneﬁts were also pub-
lished (58,59). In one young patient, ONS was com-
bined with SNS and infraorbital nerve stimulation,
which was reported to produce a dramatic improve-
ment for up to 3 years (60).
SNS alone (three patients) or combined with infra-
orbital neurostimulation (one patient) was found to be
eﬀective in a small retrospective study (61).
Comments
There is strong evidence from uncontrolled studies that
ONS is eﬀective for patients suﬀering from drug-resis-
tant CCH, and the eﬀect size is greater than in chronic
migraine, in which the moderate advantages from ONS
are not conﬁrmed in all RCTs. A 50% decrease in
attack frequency is reported in 44–88% of iCCH
patients, compared to 39–48% in chronic migraine. In
a long-term follow-up retrospective study, 80% of
iCCH patients reported experiencing a beneﬁt from
ONS compared to 42% of refractory chronic migraine
patients (62).
The eﬀect of ONS in iCCH is no more than symp-
tomatic, however, since the majority of patients
are unable to stop taking preventative drugs and
attacks recur after interruption of the stimulation (e.g.
when the battery goes ﬂat). There is no known predict-
ive factor for ONS eﬃcacy; response to GON blocks
(see above) does not predict response to ONS
(50,58,63). Nonetheless, medication overuse may be
associated with a less favourable outcome after
ONS (64).
Adverse eﬀects are frequent in ONS-treated patients.
The most prevalent are local pain and/or intolerable
paresthesias, infections, electrode displacement and
battery replacements. The latter cannot be considered
an adverse eﬀect per se, but may further increase the
cost of ONS, which is estimated at E28,000 per patient
(56). In one study, 58% of patients required at least one
lead revision (62). Because of the paresthesias produced
by the stimulation, true blinding is diﬃcult to achieve in
clinical trials, and it is thus challenging to establish the
8 Cephalalgia 0(0)
placebo eﬀect with conﬁdence. As mentioned before,
however, the superiority of subthreshold ONS over
no stimulation in chronic migraine studies and the
rapid recurrence of attacks after cessation of the stimu-
lation in cluster headache trials suggest that the clinical
beneﬁt is due to a genuine eﬀect of ONS and not to a
placebo eﬀect or to the natural history of the disease
(50,63).
The precise mode of action of ONS needs to be
determined. In a ﬂudeoxyglucose positron emission
tomography study of iCCH patients treated with
ONS for more than 6 months, the only diﬀerence
between responders and non-responders was increased
metabolism in the subgenual anterior cingulate gyrus,
suggesting that ONS modulates central pain control
centres (65).
Taken together, the available evidence suggests that
invasive ONS could be a treatment option for drug-
resistant iCCH patients. Future studies should try to
determine its advantages and disadvantages with
respect to sphenopalatine ganglion stimulation (see
Lainez, this issue) and with respect to the upcoming
non-invasive transcutaneous and transcranial neurosti-
mulation methods (see Schoenen et al., this issue).
Based on published studies, the evidence favouring
ONS in chronic migraine is less convincing, and further
studies are clearly needed in order to identify the pre-
dictors of response. According to the position state-
ment of the European Headache Federation, ONS is
advisable in iCCH; in refractory chronic migraine
patients, it is only considered to be acceptable, although
this is based on limited evidence (66).
Surgical decompressions for migraine
As mentioned in the introduction, there is scarce evi-
dence that nervous structures in the pericranium or face
play a primary causative role in headache pathogenesis,
although pain felt on the surface of the head or neck
tends to be attributed merely to referred pain from the
visceral part of the ophthalmic nerve (see above).
Nonetheless, surgical procedures to treat headache
acting directly on cranial nerves have been used for a
long time.
In the last 15 years, decompression of pericranial
nerves by sectioning adjacent muscles and sections of
superﬁcial nerve branches was repeatedly proposed as a
possible treatment for migraine patients (67–79). Up to
now, this procedure has not been attempted for other
primary headaches. In the ﬁrst retrospective study,
resection of the corrugator supercilii muscle for reju-
venation was reported to improve migraine patients
(67). It was followed by a prospective study in which
the intervention was performed in headache patients
with hypertrophy of the corrugator supercilii muscle
who had at least 50% amelioration after one injection
of 25 U botulinum toxin type A into this muscle (68).
Disappearance of headaches was reported in 66.7% of
subjects, and partial improvement was reported in the
remaining 33.3%. The latter also underwent a transec-
tion of the zygomaticotemporal branch of the trigem-
inal nerve and repositioning of the temple soft tissues.
After follow-up (222–494 days), all patients except one
had supplementary improvement. In a subsequent
unblinded prospective study, patients were allocated,
depending on the origin of pain and botulinum toxin
eﬀect, to one or a combination of four surgical proced-
ures: removal of corrugator supercilii, depressor super-
cilii and procerus muscles (90% of patients);
endoscopic removal of 3 cm of the zygomaticotemporal
branch of the trigeminal nerve (80%); resection of the
semispinalis capitis muscle and shielding of the GON
(38%); and septoplasty and inferior and/or middle tur-
binectomies (70%). Outcomes were compared to a non-
operated control group after a 1-year follow-up (69).
In the operated group, 92% of patients were
reported to have a 50% reduction in migraine head-
ache frequency and duration, while only 15.8% of con-
trols improved. At the end of a 5-year follow-up period,
88% of patients, 69.5% of whom were operated on
at three to four sides, experienced beneﬁcial eﬀects
from the surgical treatment, according to the authors
(70).
The only sham-controlled study included 75 patients
with migraine with or without aura, who reported a so-
called ‘‘trigger site’’ (i.e. a predominant site ‘‘where the
migraine headache begins and settles and corresponds
to the anatomical zone of potential irritation of the
trigeminal nerve’’) and had at least 50% amelioration
after injection of 25 U botulinum toxin into the ‘‘trig-
ger’’ area (71). They were operated on according to
their ‘‘trigger sites’’ (‘‘frontal’’, ‘‘temporal’’ or ‘‘occipi-
tal’’) and followed for 1 year. In each group, a third of
patients underwent a sham operation. In the verum arm
(n¼ 49), 83.7% of subjects from the three groups
demonstrated signiﬁcant amelioration or elimination
of headaches, whereas in the sham arm (n¼ 26),
57.7% had a similar positive outcome.
Several retrospective studies reported possible pre-
dictors of favourable outcome (72–74) or beneﬁt
from additional surgical procedures such as supra-
orbital foraminotomy (75) or ligation of the occipital
artery (76).
Some other retrospective studies of the eﬀects of sur-
gery in the frontal area in migraine are available. In the
largest one using resection of corrugator and depressor
muscles, 58.3% of 60 chronic or episodic migraineurs
had a 50% reduction in headache days at the
6-month follow-up (77). Another study reported
a 50% amelioration of headaches in 16 out of 18
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migraine patients responding to botulinum toxin and
operated on at multiple sites in various combinations
(78). Improvement after corrugator muscle resection
was also reported in nine out of ten patients who suf-
fered from frontally located ‘‘chronic daily headache’’
and improved by 50% after at least two frontal injec-
tions of botulinum toxin (79).
Comments
The proposed rationale for surgical decompression of
pericranial nerves in migraine is that compression of
these nerves induces inﬂammation and peptide release,
which may reach the meninges and hence trigger head-
aches. This rationale may gain support from recent
studies demonstrating extracranial projections of men-
ingeal aﬀerents (4).
With one exception, however, the evidence for the
eﬀectiveness of peripheral nerve decompressions in
migraine stems mostly from retrospective or prospect-
ive uncontrolled studies. A critical point is that the
migraine patients included in these studies all had
some uncommon clinical features (80), such as strictly
side-locked unilateral headache and the presence of
‘‘trigger sites’’ that are much more typical of cranial
neuralgias and tension-type headaches than of migraine
(81). Similarly, some additional symptoms that have
been used to determine the site of the interventions
are commonly found in other primary or secondary
headaches such as neuralgias, headaches attributed to
temporomandibular dysfunction, chronic tension-type
headaches, chronic/recurring rhinosinusitis, mucosal
contact points or concha bullosa and whiplash. All of
these causes of head or facial pain can aggravate
migraine and sometimes mimic it. An intervention
that is able to inﬂuence them has the potential to
improve migraine indirectly.
In addition, the strategy of selecting for surgery
patients who respond to botulinum toxin type A injec-
tions at ‘‘trigger sites’’ is rather puzzling and has no
scientiﬁc basis. In fact, most patients who were included
had episodic migraine and were reported to respond to
botulinum toxin in proportions ranging from 58% to
90% (68,69,71,79), which clearly contrasts with RCTs
of multiple pericranial and facial injections of botu-
linum toxin that show no diﬀerence with saline injec-
tions (82). Hence, it is likely that many patients were
selected for surgery on the basis of a placebo response.
This is supported by the very high placebo response of
58% found in the only sham-controlled study of per-
ipheral nerve decompression. Without scientiﬁc evi-
dence, the authors hypothesize that this placebo
response may be due to the fact that the incision and
the undermining of pericranial tissues may have
altered neurosensory functions and that some patients
may have exaggerated their preoperative symptoms
in order to increase their chances of being selected
for surgery (68,69,71,79). It is well established, how-
ever, that the placebo response in headaches is greater
with invasive procedures than with drug treatments
(83).
Given these confounding factors and methodo-
logical uncertainties, surgical decompression of periph-
eral nerves cannot be considered at the present time as
an established treatment for migraine. It remains to be
determined in future sham-controlled trials whether
such procedures may have a lasting clinical beneﬁt
that exceeds a placebo eﬀect in clinical subgroups of
selected patients.
Conclusions
Invasive interventions on pericranial nerve branches
have been used for a long time to treat headaches.
Although current knowledge on primary headache
pathophysiology favours a central nervous system dys-
function (84), such interventions could modulate the
neuronal circuits that are involved in central sensitisa-
tion and pain control, merely producing a symptomatic
non-speciﬁc eﬀect. Among primary headaches, cluster
headache appears to respond best to both GON blocks
and peripheral neuromodulation, but the treatment
responses are not necessarily correlated. In migraine,
both procedures are only marginally eﬀective, but this
may improve in the future with advances in patient
selection and treatment protocols.
Larger better-designed and comparative trials are
needed in order to evaluate the long-term eﬀects of
the invasive implantation of neurostimulators or
nerve decompressions. Eﬀective blinding is a major
challenge in such trials, as will be the comparison
with the upcoming non-invasive neurostimulation
methods.
Literature search methods
English-language publications were searched for in
PubMed up to July 2015.
The following search terms were used: ‘‘migraine
neurostimulation’’, ‘‘cluster headache neurostimula-
tion’’, ‘‘migraine neuromodulation’’, ‘‘cluster headache
neuromodulation’’, ‘‘migraine injection’’, ‘‘cluster
headache injection’’, ‘‘migraine nerve inﬁltrations’’,
‘‘cluster headache nerve inﬁltrations’’, ‘‘migraine
nerve blocks’’, ‘‘cluster headache nerve blocks’’,
‘‘migraine surgery’’, ‘‘cluster headache surgery’’ and
‘‘migraine decompression’’. All of the identiﬁed publi-
cations were individually assessed according to their
relevance to the topic. Speciﬁc exclusion criteria
included publications on single case reports and
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editorials and other review articles unless of exceptional
importance. The reference lists of identiﬁed
publications were also scrutinised for further relevant
publications.
Clinical implications
. Suboccipital inﬁltrations (or greater occipital nerve blocks) are eﬀective, evidence-based, safe and inexpen-
sive treatments for short-term prophylaxis in cluster headache patients; they may also have some eﬀect in
selected migraine patients, particularly those with ﬁxed unilateral headaches and ipsilateral autonomic
symptoms.
. Percutaneous occipital nerve stimulation (ONS) has long-term eﬃcacy in refractory chronic cluster head-
ache, but it has frequent, though reversible, adverse eﬀects, and a sham-controlled trial is not yet available.
By contrast, the evidence that ONS is eﬀective in chronic migraine is weak, although some randomised
controlled trials (RCTs) indicate that it might be beneﬁcial in subgroups of patients.
. Surgical decompression of pericranial nerves in migraine patients was reported to be superior to sham
surgery in one study, and most case series are non-controlled and published by the same group. The het-
erogeneity of included patients, selection bias and questionable inclusion criteria are major shortcomings of
these studies and do not allow us to rule out the notion that the greater part of the reported beneﬁts is due to
a placebo eﬀect. Further better-designed RCTs are needed before surgical decompressions can be recom-
mended in the treatment of selected migraine patients.
Declaration of conflicting interests
The authors declared the following potential conﬂicts of inter-
est with respect to the research, authorship, and/or publica-
tion of this article: A Ambrosini has no conﬂicts of interest. J
Schoenen is a consultant for Cefaly-Technology, St. Jude
Medical, ATI, Medtronic, AMGEN and Gedeon Richter.
Funding
The authors received no ﬁnancial support for the research,
authorship, and/or publication of this article.
References
1. Irimia P, Palma JA, Fernandez-Torron R, et al. Refrac-
tory migraine in a headache clinic population. BMC
Neurol 2011; 11: 94.
2. Whyte CA and Tepper SJ. Adverse effects of medications
commonly used in the treatment of migraine. Expert Rev
Neurother 2009; 9: 1379–1391.
3. Edvinsson L, Villalo´n CM and MaassenVanDenBrink A.
Basic mechanisms of migraine and its acute treatment.
Pharmacol Ther 2012; 136: 319–333.
4. Schueler M, Neuhuber WL, De Col R, et al. Innervation
of rat and human dura mater and pericranial tissues in
the parieto-temporal region by meningeal afferents.
Headache 2014; 54: 996–1009.
5. Schueler M, Messlinger K, Dux M, et al. Extracranial
projections of meningeal afferents and their impact on
meningeal nociception and headache. Pain 2013; 154:
1622–1631.
6. Knight G. Surgical treatment of migraine. Proc R Soc
Med 1962; 55: 172–176.
7. Matharu MS, Boes CJ and Goadsby PJ. Management of
trigeminal autonomic cephalgias and hemicrania conti-
nua. Drugs 2003; 63: 1637–1677.
8. Anthony M. The role of the occipital nerve in unilateral
headache. In: Rose FC (ed.). Current Problems in Neurol-
ogy: 4. Advances in Headache Research. London: John
Libbey, 1987, pp.257–262.
9. Kerr FWL. A mechanism to account for frontal headache
in cases of posterior fossa tumour. J Neurosurg 1961; 18:
605–609.
10. Ashkenazi A, Matro R, Shaw JW, et al. Greater occipital
nerve block using local anaesthetics alone or with triam-
cinolone for transformed migraine: a randomised com-
parative study. J Neurol Neurosurg Psychiatry 2008; 79:
415–417.
11. Dilli E, Halker R, Vargas B, et al. Occipital nerve block
for the short-term preventive treatment of migraine: a
randomized, double-blinded, placebo-controlled study.
Cephalalgia 2015; 35: 959–968.
12. Kashipazha D, Nakhostin-Mortazavi A,
Mohammadianinejad SE, et al. Preventive effect of
greater occipital nerve block on severity and frequency
of migraine headache. Glob J Health Sci 2014; 6: 209–213.
13. Inan LE, Inan N, Karadas O, et al. Greater occipital
nerve for the treatment of chronic migraine: a rando-
mized, multicenter, double-blind, parallel and placebo-
controlled study. Acta Neurol Scand 2015; doi: 10.1111/
ane.12393 [Epub ahead of print].
14. Palamar D, Uluduz D, Saip S, et al. Ultrasound-guided
greater occipital nerve block: an efficient technique in
chronic refractory migraine without aura? Pain
Physician 2015; 18: 153–162.
15. Gelfand AA, Reider AC and Goadsby PJ. Outcomes of
greater occipital nerve injections in pediatric patients with
chronic primary headache disorders. Pediatr Neurol 2014;
50: 135–139.
16. Afridi SK, Shields KG, Bhola R, et al. Greater occipital
nerve injection in primary headache syndromes – prolonged
effects from a single injection. Pain 2006; 122: 126–129.
Ambrosini and Schoenen 11
17. Weibelt S, Andress-Rothrock D, King W, et al. Subocci-
pital nerve blocks for suppression of chronic migraine:
safety, efficacy, and predictors of outcome. Headache
2010; 50: 1041–1044.
18. Tobin JA and Flitman SS. Occipital nerve blocks:
effect of symptomatic medication: overuse and
headache type on failure rate. Headache 2009; 49:
1479–1485.
19. Kinfe T, Schuss P and Vatter H. Occipital nerve block
prior to occipital nerve stimulation for refractory chronic
migraine and chronic cluster headache: myth or predic-
tion? Cephalalgia 2015; 35: 359–362.
20. Bovim G and Sand T. Cervicogenic headache, migraine
without aura and tension-type headache. Diagnostic
blockade of greater occipital and supra-orbital nerves.
Pain 1992; 51: 43–48.
21. Ashkenazi A and Young WB. The effects of greater
occipital nerve block and trigger point injection on
brush allodynia and pain in migraine. Headache 2005;
45: 350–354.
22. Young W, Cook B, Malik S, et al. The first 5 minutes
after greater occipital nerve block. Headache 2008; 48:
1126–1128.
23. Baron EP, Tepper SJ, Mays M, et al. Acute treatment of
basilar-type migraine with greater occipital nerve block-
ade. Headache 2010; 50: 1057–1059.
24. Caputi CA and Firetto V. Therapeutic blockade of
greater occipital and supraorbital nerves in migraine
patients. Headache 1997; 37: 174–179.
25. Ilhan Alp S and Alp R. Supraorbital and infraorbital
nerve blockade in migraine patients: results of 6-month
clinical follow-up. Eur Rev Med Pharmacol Sci 2013; 17:
1778–1781.
26. Cady RK, Saper J, Dexter K, et al. Long-term efficacy of
a double-blind, placebo-controlled, randomized study for
repetitive sphenopalatine blockade with bupivacaine vs
saline with the Tx360 device for treatment of chronic
migraine. Headache 2015; 55: 529–542.
27. Leroux E and Ducros A. Occipital injections for trige-
mino-autonomic cephalalgias: evidence and uncertainties.
Curr Pain Headache Rep 2013; 17: 325.
28. Anthony M. Headache and the greater occipital nerve.
Clin Neurol Neurosurg 1992; 94: 297–301.
29. Ambrosini A, Vandenheede M, Rossi P, et al.
Suboccipital injection with a mixture of rapid-
and long-acting steroids in cluster headache: a
double-blind placebo-controlled study. Pain 2005; 118:
92–96.
30. Busch V, Jakob W, Juergens T, et al. Occipital nerve
blockade in chronic cluster headache patients and func-
tional connectivity between trigeminal and occipital
nerves. Cephalalgia 2007; 27: 1206–1214.
31. Leroux E, Valade D, Taifas I, et al. Suboccipital steroid
injections for transitional treatment of patients with more
than 2 cluster headache attacks per day: a randomized,
double-blind, placebo-controlled trial. Lancet Neurol
2011; 10: 891–897.
32. Robbins MS. Peripheral nerve blocks, steroid injections
and their niche in headache medicine. Cephalalgia 2015;
25: 850–852.
33. Lambru G, Lagrata S and Matharu MS. Cutaneous
atrophy and alopecia after greater occipital nerve
injection using triamcinolone. Headache 2012; 52:
1596–1599.
34. Melzack R and Wall PD. Pain mechanisms: a new theory.
Science 1965; 150: 971–979.
35. DeSantana JM, Da Silva LF, De Resende MA, et al.
Transcutaneous electrical nerve stimulation at both high
and low frequencies activates ventrolateral periaqueduc-
tal grey to decrease mechanical hyperalgesia in arthritic
rats. Neuroscience 2009; 163: 1233–1241.
36. Bartsch T and Goadsby PJ. Increased responses in
trigeminocervical nociceptive neurons to cervical input
after stimulation of the dura mater. Brain 2003; 126:
1801–1813.
37. Serra G and Marchioretto F. Occipital nerve stimulation
for chronic migraine: a randomized trial. Pain Physician
2012; 15: 245–253.
38. Saper JR, Dodick DW, Silberstein SD, et al. Occipital
nerve stimulation for the treatment of intractable chronic
migraine headache: ONSTIM feasibility study.
Cephalalgia 2011; 31: 271–285.
39. Lipton R, Goadsby P, Cady R, et al. PRISM study:
occipital nerve stimulation for treatment-refractory
migraine. Cephalalgia 2009; 29(Suppl. 1): 30.
40. Silberstein S, Dodick D, Saper J, et al. Safety and efficacy
of peripheral nerve stimulation of the occipital nerves for
the management of chronic migraine: Results from a ran-
domized, multicenter, double-blinded, controlled study.
Cephalalgia 2012; 32: 1165–1179.
41. Dodick DW, Silberstein SD, Reed KL, et al. Safety and
efficacy of peripheral nerve stimulation of the occipital
nerves for the management of chronic migraine: long-
term results from a randomized, multicenter, double-
blinded, controlled study. Cephalalgia 2015; 35: 344–358.
42. Slotty PJ, Bara G, Kowatz L, et al. Occipital nerve stimu-
lation for chronic migraine: a randomized trial on sub-
threshold stimulation. Cephalalgia 2015; 35: 73–78.
43. Chen YF, Bramley G, Unwin G, et al. Occipital nerve
stimulation for chronic migraine – a systematic review
and meta-analysis. PLoS ONE 2015; 10(3): e0116786.
44. Reed KL, Black SB, Banta CJ 2nd, et al. Combined
occipital and supraorbital neurostimulation for the treat-
ment of chronic migraine headaches: initial experience.
Cephalalgia 2010; 30: 260–271.
45. Reed KL, Will KR, Chapman J, et al. Combined occipi-
tal and supraorbital neurostimulation for chronic
migraine headaches: an extended case series.
Cephalalgia 2011; 31(Suppl. 1): 98.
46. Burns B. ‘Dual’ occipital and supraorbital nerve stimula-
tion for primary headache. Cephalalgia 2010; 30:
257–259.
47. Reed KL, Will KR, Conidi F, et al. Concordant occipital
and supraorbital neurostimulation therapy for hemiplegic
migraine; initial experience; a case series.
Neuromodulation 2015; 18: 297–303.
48. Kovacs S, Peeters R, De Ridder D, et al. Central effects
of occipital nerve electrical stimulation studied by func-
tional magnetic resonance imaging. Neuromodulation
2011; 14: 46–55.
12 Cephalalgia 0(0)
49. Burns B, Watkins L and Goadsby PJ. Treatment of med-
ically intractable cluster headache by occipital nerve
stimulation: long-term follow-up of eight patients.
Lancet 2007; 369: 1099–1106.
50. Magis D, Allena M, Bolla M, et al. Occipital nerve stimu-
lation for drug-resistant chronic cluster headache: a pro-
spective pilot study. Lancet Neurol 2007; 6: 314–321.
51. Fontaine D, Sol JC, Raoul S, et al. Treatment of refrac-
tory chronic cluster headache by chronic occipital nerve
stimulation. Cephalalgia 2011; 31: 1101–1105.
52. Strand NH, Trentman TL, Vargas BB, et al. Occipital
nerve stimulation with the Bion microstimulator for
the treatment of medically refractory chronic cluster
headache. Pain Physician 2011; 14: 435–440.
53. Mueller OM, Gaul C, Katsarava Z, et al. Occipital nerve
stimulation for the treatment of chronic cluster headache
– lessons learned from 18 months experience. Cent Eur
Neurosurg 2011; 72: 84–89.
54. Burns B, Watkins L and Goadsby PJ. Treatment of
intractable chronic cluster headache by occipital nerve
stimulation in 14 patients. Neurology 2009; 72: 341–345.
55. Magis D, Gerardy PY, Remacle JM, et al. Sustained
effectiveness of occipital nerve stimulation in drug-resis-
tant chronic cluster headache. Headache 2011; 51:
1191–1201.
56. Mueller O, Diener HC, Dammann P, et al. Occipital
nerve stimulation for intractable chronic cluster headache
or migraine: a critical analysis of direct treatment costs
and complications. Cephalalgia 2013; 33: 1283–1291.
57. Wilbrink LA, Teernstra OP, Haan J, et al. Occipital nerve
stimulation in medically intractable, chronic cluster head-
ache. The ICON study: rationale and protocol of a ran-
domised trial. Cephalalgia 2013; 33: 1238–1247.
58. Schwedt T, Dodick D, Hentz J, et al. Occipital nerve
stimulation for chronic headache – long-term safety and
efficacy. Cephalalgia 2007; 27: 153–157.
59. Schwedt TJ, Dodick DW, Trentman TL, et al. Occipital
nerve stimulation for chronic cluster headache and hemi-
crania continua: pain relief and persistence of autonomic
features. Cephalalgia 2006; 26: 1025–1027.
60. Mammis A, Gudesblatt M and Mogilner AY. Peripheral
neurostimulation for the treatment of refractory clus-
ter headache, long-term follow-up: case report.
Neuromodulation 2011; 14: 432–435. discussion 435.
61. Vaisman J, Markley H, Ordia J, et al. The treatment of
medically intractable trigeminal autonomic cephalalgia
with supraorbital/supratrochlear stimulation: a
retrospective case series. Neuromodulation 2012; 15:
374–380.
62. Brewer AC, Trentman TL, Ivancic MG, et al. Long-term
outcome in occipital nerve stimulation patients with med-
ically intractable primary headache disorders.
Neuromodulation 2013; 16: 557–562. discussion 563–564.
63. Oh MY, Ortega J, Bellotte JB, et al. Peripheral nerve
stimulation for the treatment of occipital neuralgia and
transformed migraine using a C1-2-3 subcutaneous
paddle style electrode: a technical report.
Neuromodulation 2004; 7: 103–112.
64. Paemeleire K, Van Buyten JP, Van Buynder M, et al.
Phenotype of patients responsive to occipital nerve
stimulation for refractory head pain. Cephalalgia 2010;
30: 662–673.
65. Magis D, Bruno MA, Fumal A, et al. Central modulation
in cluster headache patients treated with occipital nerve
stimulation: an FDG-PET study. BMC Neurol 2011; 11:
25.
66. Martelletti P, Jensen RH, Antal A, et al European
Headache Federation. Neuromodulation of chronic
headaches: position statement from the European Head-
ache Federation. J Headache Pain 2013; 14: 86.
67. Guyuron B, Varghai A, Michelow BJ, et al. Corrugator
supercilii muscle resection and migraine headaches. Plast
Reconstr Surg 2000; 106: 429–434.
68. Guyuron B, Tucker T and Davis J. Surgical treatment of
migraine headaches. Plast Reconstr Surg 2002; 109:
2183–2189.
69. Guyuron B, Kriegler JS, Davis J, et al. Comprehensive
surgical treatment of migraine headaches. Plast Reconstr
Surg 2005; 115: 1–9.
70. Guyuron B, Kriegler JS, Davis J, et al. Five-year outcome
of surgical treatment of migraine headaches. Plast
Reconstr Surg 2011; 127: 603–608.
71. Guyuron B, Reed D, Kriegler JS, et al. A placebo-con-
trolled surgical trial of the treatment of migraine head-
aches. Plast Reconstr Surg 2009; 124: 461–468.
72. Larson K, Lee M, Davis J, et al. Factors contributing to
migraine headache surgery failure and success. Plast
Reconstr Surg 2011; 128: 1069–1075.
73. Liu MT, Armijo BS and Guyuron B. A comparison of
outcome of surgical treatment of migraine headaches
using a constellation of symptoms versus botulinum
toxin type A to identify the trigger sites. Plast Reconstr
Surg 2012; 129: 413–419.
74. Lee M, Monson MA, Liu MT, et al. Positive botulinum
toxin type a response is a prognosticator for migraine
surgery success. Plast Reconstr Surg 2013; 131: 751–757.
75. Chepla KJ, Oh E and Guyuron B. Clinical outcomes fol-
lowing supraorbital foraminotomy for treatment of fron-
tal migraine headache. Plast Reconstr Surg 2012; 129:
656e–662e.
76. Chmielewski L, Liu MT and Guyuron B. The role of
occipital artery resection in the surgical treatment of
occipital migraine headaches. Plast Reconstr Surg 2013;
131: 351e–356e.
77. Dirnberger F and Becker K. Surgical treatment of
migraine headaches by corrugator muscle resection.
Plast Reconstr Surg 2004; 114: 652–657.
78. Poggi JT, Grizzell BE and Helmer SD. Confirmation of
surgical decompression to relieve migraine headaches.
Plast Reconstr Surg 2008; 122: 115–122.
79. de Ru JA, Schellekens PP and Lohuis PJ. Corrugator
supercilii transection for headache emanating from the
frontal region: a clinical evaluation of ten patients.
J Neural Transm 2011; 118: 1571–1574.
80. D’Amico D, Leone M and Bussone G. Side-locked uni-
laterality and pain localization in long-lasting headaches:
migraine, tension-type headache, and cervicogenic head-
ache. Headache 1994; 34: 526–530.
81. Headache Classification Committee of the International
Headache Society (IHS). The International Classification
Ambrosini and Schoenen 13
of Headache Disorders, 3rd edition (beta version).
Cephalalgia 2013; 33: 629–808.
82. Jackson JL, Kuriyama A and Hayashino Y. Botulinum
toxin A for prophylactic treatment of migraine and ten-
sion headaches in adults: a meta-analysis. JAMA 2012;
307: 1736–1745.
83. Meissner K, Fassler M, Rucker G, et al. Differential effect-
iveness of placebo treatments: a systematic reviewofmigraine
prophylaxis. JAMA Intern Med 2013; 173: 1941–1951.
84. De Tommaso M, Ambrosini A, Brighina F, et al. Altered
sensory processing in migraine. Nat Rev Neurol 2014; 10:
144–155.
14 Cephalalgia 0(0)
